BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 29262669)

  • 1. Advances in the understanding and management of T-cell prolymphocytic leukemia.
    Laribi K; Lemaire P; Sandrini J; Baugier de Materre A
    Oncotarget; 2017 Nov; 8(61):104664-104686. PubMed ID: 29262669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases.
    Hu Z; Medeiros LJ; Xu M; Yuan J; Peker D; Shao L; Tang Z; Mai B; Thakral B; Rios A; Hu S; Wang W
    Am J Clin Pathol; 2023 Apr; 159(4):325-336. PubMed ID: 36883805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell Prolymphocytic Leukemia.
    Matutes E
    Cancer Control; 1998 Jan; 5(1):19-24. PubMed ID: 10761013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia.
    Kiel MJ; Velusamy T; Rolland D; Sahasrabuddhe AA; Chung F; Bailey NG; Schrader A; Li B; Li JZ; Ozel AB; Betz BL; Miranda RN; Medeiros LJ; Zhao L; Herling M; Lim MS; Elenitoba-Johnson KS
    Blood; 2014 Aug; 124(9):1460-72. PubMed ID: 24825865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small cell variant of T-cell prolymphocytic leukemia with a gammadelta immunophenotype.
    Toyota S; Nakamura N; Dan K
    Int J Hematol; 2005 Jan; 81(1):66-8. PubMed ID: 15717692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene.
    Sun S; Fang W
    Biomed Pharmacother; 2020 Jun; 126():110107. PubMed ID: 32247279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism.
    Magro CM; Morrison CD; Heerema N; Porcu P; Sroa N; Deng AC
    J Am Acad Dermatol; 2006 Sep; 55(3):467-77. PubMed ID: 16908353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B and T cell prolymphocytic leukaemia.
    Cross M; Dearden C
    Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell receptor gammadelta T-cell leukemia with the morphology of T-cell prolymphocytic leukemia and a postthymic immunophenotype.
    Sugimoto T; Imoto S; Matsuo Y; Kojima K; Yasukawa M; Murayama T; Kohfuku J; Mizuno I; Yakushijin K; Sada A; Nishimura R; Koizumi T
    Ann Hematol; 2001 Dec; 80(12):749-51. PubMed ID: 11797117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of T cell prolymphocytic leukemia involving blast transformation.
    Ichikawa K; Noguchi M; Imai H; Sekiguchi Y; Wakabayashi M; Sawada T; Komatsu N
    Int J Hematol; 2011 May; 93(5):667-672. PubMed ID: 21505955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide for T-Cell Prolymphocytic Leukemia after Alemtuzumab Induction Therapy: A Case Report.
    Okada N; Yamamoto R; Maruoka H; Himeno M; Hiramoto N; Ishikawa T
    Case Rep Oncol; 2023; 16(1):604-612. PubMed ID: 37900793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment.
    Gutierrez M; Bladek P; Goksu B; Murga-Zamalloa C; Bixby D; Wilcox R
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 14q11 abnormality and trisomy 8q are not common in Japanese T-cell prolymphocytic leukemia.
    Kojima K; Kobayashi H; Imoto S; Nakagawa T; Matsui T; Kawachi Y; Oda K; Yano T; Kobayashi H; Noguchi M; Hara M; Oshimi K
    Int J Hematol; 1998 Oct; 68(3):291-6. PubMed ID: 9846013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.
    Collignon A; Wanquet A; Maitre E; Cornet E; Troussard X; Aurran-Schleinitz T
    Curr Oncol Rep; 2017 Apr; 19(4):29. PubMed ID: 28324286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia.
    Hu Z; Medeiros LJ; Fang L; Sun Y; Tang Z; Tang G; Sun T; Quesada AE; Hu S; Wang SA; Pei L; Lu X
    Am J Hematol; 2017 May; 92(5):441-447. PubMed ID: 28194886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical and Immunophenotypic Properties of Small Cell Variant of T-cell Prolymphocytic Leukemia].
    Yu YP; Wang LP; Song P; Mei JG; An ZM; Zhou XG; Li F; Tang YM; Zhai YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):8-15. PubMed ID: 28245368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delineation of clinical course, outcomes, and prognostic factors in patients with T-cell prolymphocytic leukemia.
    Rose A; Zhang L; Jain AG; Poovathukaran Babu A; Sokol L; Saeed H; Mo Q; Fan W; Zhang X
    Am J Hematol; 2023 Jun; 98(6):913-921. PubMed ID: 36964941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A patient with white blood cell counts more than a million: A diagnostic and therapeutic challenge.
    Figueroa-Jiménez LA; Cabrera-Márquez AL; Báez-Díaz L; Cáceres-Perkins W
    Bisturi (S Juan); 2016; 2016():12-16. PubMed ID: 29238632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia.
    Herling M; Patel KA; Teitell MA; Konopleva M; Ravandi F; Kobayashi R; Jones D
    Blood; 2008 Jan; 111(1):328-37. PubMed ID: 17890451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Smoldering T-prolymphocytic Leukemia: A Case Report and a Review of the Literature.
    Gjelberg HK; Helgeland L; Liseth K; Micci F; Sandnes M; Russnes HG; Reikvam H
    Curr Oncol; 2023 Nov; 30(11):10007-10018. PubMed ID: 37999147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.